0000914190-20-000403.txt : 20201112 0000914190-20-000403.hdr.sgml : 20201112 20201112185949 ACCESSION NUMBER: 0000914190-20-000403 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20201109 FILED AS OF DATE: 20201112 DATE AS OF CHANGE: 20201112 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Hippel James CENTRAL INDEX KEY: 0001603594 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-17272 FILM NUMBER: 201308558 MAIL ADDRESS: STREET 1: 614 MCKINLEY PLACE NE CITY: MINNEAPOLIS STATE: MN ZIP: 55413 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: BIO-TECHNE Corp CENTRAL INDEX KEY: 0000842023 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 411427402 STATE OF INCORPORATION: MN FISCAL YEAR END: 0630 BUSINESS ADDRESS: STREET 1: 614 MCKINLEY PL N E CITY: MINNEAPOLIS STATE: MN ZIP: 55413 BUSINESS PHONE: 6123798854 MAIL ADDRESS: STREET 1: 614 MCKINLEY PLACE NE CITY: MINNEAPOLIS STATE: MN ZIP: 55413 FORMER COMPANY: FORMER CONFORMED NAME: TECHNE CORP /MN/ DATE OF NAME CHANGE: 19920703 4 1 edgar.xml PRIMARY DOCUMENT X0306 4 2020-11-09 0000842023 BIO-TECHNE Corp TECH 0001603594 Hippel James 614 MCKINLEY PLACE N.E. MINNEAPOLIS MN 55413 0 1 0 0 Chief Financial Officer Common Stock 2020-11-09 4 M 0 3600 106.59 A 12737 D Common Stock 2020-11-09 4 S 0 1100 306.8127 D 11637 D Common Stock 2020-11-09 4 S 0 100 307.74 D 11537 D Common Stock 2020-11-09 4 S 0 1098 310.5531 D 10439 D Common Stock 2020-11-09 4 S 0 1002 311.598 D 9437 D Common Stock 2020-11-09 4 S 0 300 312.5833 D 9137 D Common Stock 2020-11-11 4 M 0 7391 106.59 A 16528 D Common Stock 2020-11-11 4 S 0 6291 306.9264 D 10237 D Common Stock 2020-11-11 4 S 0 1100 307.7769 D 9137 D Stock Options (Right to Buy) 106.59 2020-11-09 4 M 0 3600 0 D 2023-08-18 Common Stock 3600 67333 D Stock Option (Right to Buy) 106.59 2020-11-11 4 M 0 9137 0 D 2023-08-18 Common Stock 9137 58196 D Stock Options (Right to Buy) 125.05 2024-08-09 Common Stock 24460 24460 D Stock Options (Right to Buy) 125.05 2024-08-09 Common Stock 32613 32613 D Restricted Stock Units Common Stock 3383 3383 D Stock Options (Right to Buy) 177.32 2025-08-08 Common Stock 18066 18066 D Stock Options (Right to Buy) 177.32 2025-08-08 Common Stock 24089 24089 D Restricted Stock Units Common Stock 3938 3938 D Stock Options (Right to Buy) 190.41 2026-08-07 Common Stock 19936 19936 D Stock Options (Right to Buy) 190.41 2026-08-07 Common Stock 26581 26581 D Restricted Stock Units Common Stock 3219 3219 D Stock Options (Right to Buy) 267.87 2027-08-05 Common Stock 14360 14360 D Stock Options (Right to Buy) 267.87 2027-08-05 Common Stock 19147 19147 D Stock Options (Right to Buy) 267.87 2027-08-05 Common Stock 8325 8325 D Stock Options (Right to Buy) 267.87 2027-08-05 Common Stock 8325.0 8325.0 D The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $306.50 to $307.40, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $307.74 to $307.74, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $310.13 to $311.09, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $311.24 to $311.88, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $312.38 to $312.78, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $306.51 to $307.505, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $307.54 to $308.075, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Each restricted stock unit represents a contingent right to receive one share of Bio-Techne Corporation common stock. Fully exercisable. Options to purchase 8,153 shares vest on each of 8/9/2018, 8/9/2019, 8/9/2020 and options to purchase 8,154 shares vest on 8/9/2021. Vests in full or in part on 8/8/2021 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Options to purchase 6,023 shares vest on 8/8/2019 and options to purchase 6,022 shares vest on each of 8/8/2020, 8/8/2021 and 8/8/2022. Vests in full or in part on 8/7/2022 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Options to purchase 6,646 shares vest on 8/7/2020 and options to purchase 6,645 shares vest on each of 8/7/2021, 8/7/2022 and 8/7/2023. Vests in full or in part on 8/5/2023 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Options to purchase 4,787 shares vest on each of 8/5/2021, 8/5/2022 and 8/5/2023 and options to purchase 4,786 shares vest on 8/5/2024. Options to purchase 2,775 shares vest on each of 8/5/2021, 8/5/2022 and 8/5/2023. Vests in full on the date performance of certain product revenue goals during the period of fiscal 2021-2023 is certified by the Administrator, in no event earlier than 8/5/2021. /s/ Brenda S. Furlow, Attorney-in-Fact for James Hippel pursuant to Power of Attorney previously filed. 2020-11-12